BLOOMBERG: Pfizer Cherry-Picks Cancer Drug Rights From Merck

  

Bloomberg Intelligence’s Sam Fazeli reports on a deal between Merck and Pfizer over the rights to a possible cancer drug. He speaks with Jonathan Ferro on Bloomberg Television’s “On The Move.”